Emerging Markets Earnings Roundup: Bayer, Teva, Mylan (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Bayer attributes record global sales in its 150-year history to emerging markets and new products such as Xarelto; Teva expands global footprint, and Mylan focuses on its injectables business in emerging markets.
You may also be interested in...
Bayer Aims For Global OTC Lead With Bolt-On Acquisition Plans
Chairman Marijn Dekkers says the German company believes strong organic growth and consumer health pick-ups will help Bayer become the world leader in OTCs.
New Products, Emerging Markets Spur Pharmaceutical Growth For Bayer
During its recent earnings call, the German conglomerate pointed to five drugs recently launched or now awaiting regulatory approval as driving its pharmaceutical sales growth from 2013 to 2015, along with strengthening performance in emerging markets.
Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden
Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.